ESMO Breast 2022 | ELEANOR: observing real-life extended adjuvant therapy with neratinib and concurrent use of CONKADO

Nadia Harbeck, MD, PhD, Ludwig Maximilians University – Grosshadern, Munich, Germany, discusses the multi-national, prospective, non-interventional ELEANOR (NCT04388384) study observing real-life extended adjuvant treatment with neratinib and concurrent use of the eHealth solution CANKADO, in patients with early-stage HR-positive, HER2-overexpressed/amplified breast cancer. The primary objective was patients’ adherence to neratinib treatment. CONKADO is an application developed to support the communication between the patient and physician. With proactive management, the side-effect of diarrhea significantly decreased and patients were observed to opt for neratinib. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.